Pharmaxis Awarded Two ARC Linkage Grants for Fibrotic Research

5th Jul 13

Release Date: 05/07/2013 12:00am

Pharmaceutical company Pharmaxis (ASX:PXS) today announced that two of its research projects conducted in conjunction with the University of Sydney have been awarded funding under the Australian Research Council (ARC) Linkage Projects scheme.

Leading Australian renal physician Professor Carol Pollock is heading an investigation of the utility of Pharmaxis compound PXS-4728A in treating renal fibrosis, while in a separate project  Associate Professors Paul Young and Daniela Traini, and Dr Brian Oliver will work on developing  advanced inhalation technology to deliver  Pharmaxis’ compounds to underlying fibrotic cells in the lung.

The ARC Scheme will provide funding of $405,646 and $370,000 for the two projects respectively, over three years which will match expenditure by Pharmaxis.

Read full media release - pdf

Categories: News and Media